A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00145171|
Recruitment Status : Completed
First Posted : September 5, 2005
Last Update Posted : September 5, 2005
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Drug: apomorphine HCl injection||Phase 3|
The primary objective of this study was to determine the electrocardiographic and orthostatic effects of apomorphine during controlled in-patient dose introduction in apomorphine-naïve late stage Parkinson’s disease patients. Although safety observations represented the primary objective of the study, a control group was considered essential to properly interpret adverse events that occurred during dose titration. Additional data comparing the efficacy and safety of subcutaneous apomorphine, placebo and standard antiparkinson (anti-PD) therapy was derived from this experience.
This was a two-phase study that involved a controlled in-office dose titration phase followed by a 6-month outpatient open-label treatment phase. During the in-patient dose titration phase, subjects were evaluated on separate days for the response to single doses of medication administered during an observed “Off” event (defined as first “Off” event that occurs at least one hour after administration of the normal morning dose of oral antiparkinson medication). Evaluation of the acute response to oral anti-PD medication (Baseline) and to apomorphine dose escalation between 2 and 10 mg (Titration Visits) was conducted under unblinded conditions. At the 0.4-mL titration level, placebo was randomly introduced under double-blind crossover conditions.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||56 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Orthostatic Changes Upon Apomorphine Dose Initiation in Late Stage Parkinson’s Disease Patients. A Dose Escalation Study With a Double-Blind Placebo-Controlled Efficacy Determination at 4 Mg.|
|Study Start Date :||February 2001|
|Study Completion Date :||August 2002|
- Entire Study:
- Adverse event assessments
- For Crossover portion of placebo-controlled 4mg dose comparison:
- Change in Unified Parkinson's Disease Rating Scale (UPDRS) at 20 minutes after dosing
- 1. Change in UPDRS Motor Score from pre-dose to 40 and 90 minutes after dosing;
- 2. Area under the curve (AUC) for UPDRS Motor Scores at 0, 20, 40 and 90 minutes;
- 3. Change in Dyskinesia Assessment at 0, 20, 40, and 90 minutes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00145171
|Study Director:||Will Sullivan||Mylan Bertek Pharmaceuticals|